Literature DB >> 16100402

Pyrosequencing of clinically relevant polymorphisms.

Sharon Marsh1, Cristi R King, Adam A Garsa, Howard L McLeod.   

Abstract

The data generated from the Human Genome Project has led to an explosion of technology for low-, medium-, and high-throughput genotyping methods. Pyrosequencing is a genotyping assay based on sequencing by synthesis. Short runs of sequence around each polymorphism are generated, allowing for internal controls for each sample. Pyrosequencing can also be used to identify tri-allelic, indel, and short-repeat polymorphisms, as well as determining allele percentages for methylation or pooled sample assessment. Assays details for Pyrosequencing of clinically relevant polymorphisms are described in this chapter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100402     DOI: 10.1385/1-59259-957-5:097

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  30 in total

1.  Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.

Authors:  Alessandro Schipani; Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Marco Simiele; Stefano Bonora; Sonia Rodríguez Novoa; Lorena Cuenca; Vincent Soriano; Nitipatana Chierakul; Natpratou Saguenwong; Charoen Chuchuttaworn; Janelle M Hoskins; Anne M Dvorak; Howard L McLeod; Gerry Davies; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

Authors:  Howard L McLeod; Daniel J Sargent; Sharon Marsh; Erin M Green; Cristi R King; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Stephen N Thibodeau; Axel Grothey; Roscoe F Morton; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

3.  Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

Authors:  D Neil Hayes; Amy S Lucas; Tawee Tanvetyanon; Monika K Krzyzanowska; Christine H Chung; Barbara A Murphy; Jill Gilbert; Ranee Mehra; Dominic T Moore; Arif Sheikh; Janelle Hoskins; Michele C Hayward; Ni Zhao; Wendi O'Connor; Karen E Weck; Roger B Cohen; Ezra E W Cohen
Journal:  Clin Cancer Res       Date:  2012-01-12       Impact factor: 12.531

4.  Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Authors:  Kevin C Brown; Mina C Hosseinipour; Janelle M Hoskins; Ranjit K Thirumaran; Hsiao-Chuan Tien; Ralf Weigel; Jean Tauzie; Ida Shumba; Jatinder K Lamba; Erin G Schuetz; Howard L McLeod; Angela D M Kashuba; Amanda H Corbett
Journal:  Pharmacogenomics       Date:  2011-11-23       Impact factor: 2.533

5.  Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner.

Authors:  Sharon Cresci; Gerald W Dorn; Philip G Jones; Amber L Beitelshees; Allie Y Li; Petra A Lenzini; Michael A Province; John A Spertus; David E Lanfear
Journal:  J Am Coll Cardiol       Date:  2012-06-13       Impact factor: 24.094

6.  The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.

Authors:  K J Burghardt; R Pop-Busui; M J Bly; T B Grove; S F Taylor; V L Ellingrod
Journal:  Clin Transl Sci       Date:  2012-11-01       Impact factor: 4.689

7.  DNA methylotype analysis in colorectal cancer.

Authors:  Jinsheng Yu; Robert R Freimuth; Robert Culverhouse; Sharon Marsh; Mark A Watson; Howard L McLeod
Journal:  Oncol Rep       Date:  2008-10       Impact factor: 3.906

8.  Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes.

Authors:  Sharon Cresci; Philip G Jones; Carmen C Sucharov; Sharon Marsh; David E Lanfear; Adam Garsa; Michael Courtois; Carla J Weinheimer; Jun Wu; Michael A Province; Daniel P Kelly; Howard L McLeod; John A Spertus
Journal:  Pharmacogenomics       Date:  2008-10       Impact factor: 2.533

9.  Clinical and genetic modifiers of long-term survival in heart failure.

Authors:  Sharon Cresci; Reagan J Kelly; Thomas P Cappola; Abhinav Diwan; Daniel Dries; Sharon L R Kardia; Gerald W Dorn
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

10.  Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.

Authors:  Hanna K Sanoff; Daniel J Sargent; Erin M Green; Howard L McLeod; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.